What's Happening?
MoonLake Immunotherapeutics has announced positive topline results from its Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis. The trial met all clinical endpoints at Week 16, with significant improvements
in ACR50, ACR20, MDA, and PASI90 responses. Sonelokimab demonstrated a favorable safety profile, consistent with previous studies. The trial will continue until Week 52, with full results expected in the first half of 2027.
Why It's Important?
The successful results from the IZAR-1 trial highlight sonelokimab's potential as a leading treatment for psoriatic arthritis, a condition with significant unmet medical needs. The drug's ability to address multiple disease domains could improve patient outcomes and quality of life. MoonLake's focus on inflammatory diseases positions it to capture a substantial share of the multi-billion dollar market for psoriatic arthritis treatments.
What's Next?
MoonLake will continue the IZAR-1 trial to evaluate the long-term efficacy and safety of sonelokimab. The company also plans to complete enrollment for the IZAR-2 trial in TNF-refractory patients by Q3 2026. These efforts will support regulatory submissions and potential market entry, further establishing MoonLake's presence in the inflammatory disease space.
